UroAlert - GU Oncology Daily

July 08, 2026

Videos

Peer-to-Peer Clinical Conversations

CORE-008 Cohort CX: Early Results of Cretostimogene plus Gemcitabine in BCG-Unresponsive and BCG-Exposed NMIBC - Trinity Bivalacqua

Trinity Bivalacqua

Trinity Bivalacqua discusses CORE-008 Cohort CX data, a phase 2 study of cretostimogene combined with intravesical gemcitabine in 55 BCG-unresponsive and BCG-exposed patients with CIS, T1, and TA disease.

View

Randomized Trial of Blue Light Versus White Light TURBT with Urinary Tumor DNA Testing - Armine Smith & Meghan McNamara

Armine Smith

Meghan McNamara and Armine Smith describe a randomized study combining blue-light TURBT with UroAmp urinary tumor DNA testing.

View

Beyond the Abstracts

Advances and Challenges of PET Imaging in Bladder Cancer-an Update and Future Trends - Beyond the Abstract

Impact of Brain Metastases on Systemic Renal Cell Carcinoma Treatment Outcomes: A Systematic Literature Review - Beyond the Abstract

Conference Coverage

ASCO 2026: Microbial Dysbiosis as Predictor of Benefit from CBM588 as an Adjunct to Immune Checkpoint Blockade-Based First Line Therapies in Metastatic RCC

AUA 2026: MoonRISe-2, a Phase 2 Dose Expansion Within the Study of Erdafitinib Intravesical Drug Releasing System (TAR-210) for Localized Bladder Cancer: Study Design and Baseline Characteristics

AUA 2026: Evaluating Deep Early Tumor Shrinkage in Metastatic Upper Tract Urothelial Carcinoma Treated with Enfortumab Vedotin plus Pembrolizumab

EAU 2026: Predicting Progression in BCG-Naïve High-Risk Non Muscle Invasive Bladder Cancer Using PROGRxN-BCa: An International Evaluation Study

ASCO 2026: Bulumtatug Fuvedotin (BFv; 9MW2821) + Toripalimab in Perioperative Patients with MIBC: Results of Cohort a from a Phase 2 Study

Articles

Editor Selected Abstracts and Commentaries

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

UroAlert - GU Oncology Daily

Bladder Cancer

Renal Cancer

Prostate Cancer

Testicular Cancer

Login